AstraZeneca and Daiichi Sankyo’s Enhertu Eyes 50% Of Breast Cancer Market Following HER2-Low Data
Executive Summary
Transformative product is the first to demonstrate benefit in HER2-low metastatic breast cancer, broadening its market potential to nearly half of all breast cancers.
You may also be interested in...
Enhertu Goes Into High Gear With HER2-Low Breast Cancer Approval
AstraZeneca and partner Daiichi Sankyo obtain the first approval for targeted therapy in HER2-low metastatic breast cancer for Enhertu, about four months ahead of the FDA action date.
ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm
The results of DESTINY-Breast04 could impact survival for approximately 50% of patients diagnosed with metastatic breast cancer today, principal investigator Modi said at the American Society of Clinical Oncology annual meeting.
Five Late-Breaking Studies To Look Out For At ASCO
Ahead of the American Society of Clinical Oncology meeting in early June, analysts at Biomedtracker have highlighted select high-impact late-breaking abstracts that are due to presented, including therapies from AbbVie, Gilead Sciences, Pfizer, Takeda, Amgen, AstraZeneca and Daiichi Sankyo.